by Sarah Moniz | Jun 13, 2018 | News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
by Sarah Moniz | May 18, 2018 | News
PROVIDENCE, R.I., May 18, 2018 /PRNewswire/ — The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant. The funding will enable...
